Zobrazeno 1 - 10
of 13
pro vyhledávání: '"mertenil"'
Autor:
A A Malov, L I Feiskhanova
Publikováno v:
Системные гипертензии, Vol 13, Iss 2, Pp 24-27 (2016)
In article possibility of an assessment of efficiency of therapy by the reproduced drug Mertenil of production of JSC Gideon Richter (Hungary) appointed for the purpose of primary prevention of the cardiovascular diseases. Increase of level of lipopr
Externí odkaz:
https://doaj.org/article/559497bb2656405bb0b786a27b61da81
Autor:
Malov A.A., Feiskhanova L.I.
Publikováno v:
Системные гипертензии, Vol 13, Iss 2, Pp 24-27 (2016)
In article possibility of an assessment of efficiency of therapy by the reproduced drug Mertenil of production of JSC Gideon Richter (Hungary) appointed for the purpose of primary prevention of the cardiovascular diseases. Increase of level of lipopr
Externí odkaz:
https://doaj.org/article/2b39e4bd73d3425db7b7ef5cbc4b295b
Publikováno v:
КардиоСоматика, Vol 6, Iss 1, Pp 36-45 (2015)
Atherosclerosis and it’s clinical implications (myocardial infarction, stroke, intermittent lameness) is a serious medico-social problem in Russia. Statins (or HMG-CoA reductase inhibitors) are the first-choice agents to prevent cardiovascular dise
Externí odkaz:
https://doaj.org/article/6e6e4de8a7ec4cc7b82beb166497ca78
Publikováno v:
Системные гипертензии, Vol 11, Iss 2, Pp 42-47 (2014)
Familial hypercholesterolemia (FH) is an inherited disease that results in high levels of total cholesterol, causing the risk of early ischemic heart disease (IHD). Rosuvastatin is the high-potency hypolipidemic agent of HMG-CoA reductase inhibitors
Externí odkaz:
https://doaj.org/article/2f825673a4af4de0b4dcb7ff13d0e88b
Autor:
V. V. Kukharchuk, P. P. Malyshev
Publikováno v:
Евразийский Кардиологический Журнал, Vol 0, Iss 2, Pp 35-42 (2013)
In the article the authors consider some concerns of clinical efficacy and safety of rosuvastatin - the most powerful representative of the group of statins. The review contains the results of clinical trials, demonstrating its high lipid-lowering ef
Externí odkaz:
https://doaj.org/article/c9d36b8e249647f2b99cc6028157cddb
Publikováno v:
Medicine of Ukraine; № 9(205) (2016); 17-20
Лекарства Украины; № 9(205) (2016); 17-20
Ліки України; № 9(205) (2016); 17-20
Лекарства Украины; № 9(205) (2016); 17-20
Ліки України; № 9(205) (2016); 17-20
The article deals with the results of researches on the effect of the combination of ACE inhibitor (lisinopril) and calcium antagonist (amlodipine) when used in patients with high or very high cardiovascular risk. There is also considered the possibi
Autor:
L I Feiskhanova, A A Malov
Publikováno v:
Системные гипертензии, Vol 13, Iss 2, Pp 24-27 (2016)
In article possibility of an assessment of efficiency of therapy by the reproduced drug Mertenil of production of JSC Gideon Richter (Hungary) appointed for the purpose of primary prevention of the cardiovascular diseases. Increase of level of lipopr
Publikováno v:
КардиоСоматика, Vol 6, Iss 1, Pp 36-45 (2015)
Atherosclerosis and it’s clinical implications (myocardial infarction, stroke, intermittent lameness) is a serious medico-social problem in Russia. Statins (or HMG-CoA reductase inhibitors) are the first-choice agents to prevent cardiovascular dise
Publikováno v:
Системные гипертензии, Vol 11, Iss 2, Pp 42-47 (2014)
Familial hypercholesterolemia (FH) is an inherited disease that results in high levels of total cholesterol, causing the risk of early ischemic heart disease (IHD). Rosuvastatin is the high-potency hypolipidemic agent of HMG-CoA reductase inhibitors
Publikováno v:
Медицинские новости.
Приведен обзор, посвященный гиполипидемической эффективности розувастатина, а также нелипидным, так называемым плейо-тропным эффектам